Lupin R&D Structure

An Overview
The R&D infrastructure at Lupin is well suited
for its present & future developments

 Lupin Research Park (LRP) at Pune, spread across 19 acres is

the hub of the Company’s global research activity,
 The Company also has an advanced Research & Development
facility - Kyowa Pharmaceutical Industry Co. Ltd, located at
Osaka, Japan,
 Has a scientific pool of close to 600 researchers,
 During 2008-09, the total investment of the Company in R&D
was over Rs.2,669 mn, 7.1% of consolidated net sales.
Over the years Lupin has increased its R&D spend,
in order to remain competitive in the changing
scenarios
Lupin pays special attention to the
development of orphan drugs

 Majorly Lupin is entering into several JVs to develop

orphan drugs, due to their immense potential,
 Orphan drugs are drugs for those conditions that affect
less than 200,000 people, in the USA and the company
discovering and developing a drug for such a condition
gets to market the product without competition for 7
years, as well as obtains tax incentives on the Clinical
Trials, and studies.
 The most recent developments include:
Lupin & Aspen forming a 50-50 JV on TB drugs.
Lupin has a highly diversified R&D Structure

Lupin
R&D
Biotechnol
ogy

Novel Drug Generics

Discovery &
Development Research

Intellectual
Property Mgmt. ADDS
Bio Research
Center
Generics Formulation consists of mainly 2
divisions

Formulation Research Process Research

Strategy to develop Focusing on
niche, difficult to biocatalysis: metal
develop products. mediated chemical
Capturing First to File entry,
Opportunities of Also focusing on the
different therapies, overall collaborative
because barriers to approach.
entry are multiple in
niche markets.
The R&D Structure
Lupin Bio Research
Advanced Drug Delivery Center
Systems
Research on
Concentrating on:
Bioavailability,
Invasive to Non-invasive
Biotechnology,
therapies
Oral Controlled Release Chiral Molecules,
Solublisable Bioavailability Pathology laboratory.
Enhancement
Pulmonary Drug Delivery
Taste-masking
Also developing laser
drilling Nanotechnology.
Biotechnology Research is proving to be a
major differentiating factor
Novel Drug Delivery &
Development Biotechnology
Developing new and innovative Major differentiating factor
healthcare products catering to new independent Biotech
under-served disease areas, facility,
Focusing on disease segments Lupin is also exploring
like: collaborative arrangements
Migraine
to expedite its business in
Type II Diabetes
this segment,
Psoriasis
targeting both at Biosimilar
TB
and New Biological Entities
Rheumatoid
(NBEs)
Goal: world - class in any of the
therapies and target areas that
the Company works in.
NCE Pipeline for Lupin
The importance of IPM is well understood
by Lupin

 Intellectual Property Management:

 Identifies lucrative marketing opportunities along with the
R&D team,
 Their aim is to put in place a well-differentiated, value-based
product pipeline, with a strong accent on controlled release,
exclusive and unique first-to-file and well thought out niche
filings.
 It has also led the identification of products in the Oral
Contraceptives and Ophthalmic space
The overall patents filed by Lupin
THANK YOU